The Brugada syndrome

Current Opinion in Cardiology

Volumn 22, Issue 3, 2007, Pages 163-170

  Rossenbacker, Tom ^a   Priori, Silvia G ^a,b  

^a IRCCS   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Brugada syndrome; Risk stratification; SCN5A; Sudden cardiac death

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPIVACAINE; CALCIUM CHANNEL L TYPE; COCAINE; DEXTROPROPOXYPHENE; ISOPRENALINE; LITHIUM; METHOXAMINE; PINACIDIL; PROPOFOL; QUINIDINE; SODIUM CHANNEL;

ALCOHOL CONSUMPTION; AUTONOMIC NERVOUS SYSTEM; BRUGADA SYNDROME; CATHETER ABLATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ELECTROSTIMULATION; FOLLOW UP; GENE MUTATION; GENETICS; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERPYREXIA; LOW DRUG DOSE; PATHOPHYSIOLOGY; PHENOTYPE; PR INTERVAL; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; REVIEW; SODIUM CURRENT; ST SEGMENT ELEVATION; SYNCOPE;

AUTONOMIC NERVOUS SYSTEM; BRUGADA SYNDROME; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; GENETIC RESEARCH; HUMANS; MUSCLE PROTEINS; RISK ASSESSMENT; RISK FACTORS; SODIUM CHANNELS;

EID: 34147197389     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328112f345     Document Type: Review

References (75)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992; 20:1391-1396.
2. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111:659-670.
3. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 2000; 102:2509-2515.
4. Meregalli PG, Ruijter JM, Hofman N, et al. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 2006; 17:857-864.
5. Miyamoto K, Yokokawa M, Tanaka K, et al. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol 2007; 99:53-57.
6. Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol 2000; 11:95-98.
7. Takagi M, Aihara N, Takaki H, et al. Clinical characteristics of patients with spontaneous or inducible ventricular fibrillation without apparent heart disease presenting with J wave and ST segment elevation in inferior leads. J Cardiovasc Electrophysiol 2000; 11:844-848.
8. Ogawa M, Kumagai K, Yamanouchi Y, et al. Spontaneous onset of ventricular fibrillation in Brugada syndrome with J wave and ST-segment elevation in the inferior leads. Heart Rhythm 2005; 2:97-99.
9. Ueyama T, Shimizu A, Esato M, et al. A case of a concealed type of Brugada syndrome with a J wave and mild ST-segment elevation in the inferolateral leads. J Electrocardiol 2007; 40:39-42.
10. Potet F, Mabo P, Le Coq G, et al. Novel Brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. J Cardiovasc Electrophysiol 2003; 14:200-203.
11. Antzelevitch C. Late potentials and the Brugada syndrome. J Am Coll Cardiol 2002; 39:1996-1999.
12. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002; 40:350-356.
13. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23:20-21.
14. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104:3081-3086.
15. Rossenbacker T, Carroll SJ, Liu H, et al. Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death. Heart Rhythm 2004; 1:610-615.
16. Tan HL, Meregalli PG. Lethal ECG changes hidden by therapeutic hypothermia. Lancet 2007; 369:78.
17. Gavrielatos G, Letsas KP, Pappas LK, et al. Brugada electrocardiographic pattern induced during febrile state with marked leukocytosis. Pacing Clin Electrophysiol 2007; 30:135-136.
18. Ortega-Carnicer J, Benezet J, Ceres F. Fever-induced ST-segment elevation and T-wave alternans in a patient with Brugada syndrome. Resuscitation 2003; 57:315-317.
19. Mok NS, Priori SG, Napolitano C, et al. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol 2003; 14:407-411.
20. Ikeda T, Abe A, Yusu S, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol 2006; 17:602-607.
21. Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J Electrocardiol 2001; 34:345-349.
22. Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000; 75:845-849.
23. Mivelaz Y, Di Bernardo S, Pruvot E, et al. Brugada syndrome in childhood: a potential fatal arrhythmia not always recognised by paediatricians. A case report and review of the literature. Eur J Pediatr 2006; 165:507-511.
24. Priori SG, Napolitano C, Giordano U, et al. Brugada syndrome and sudden cardiac death in children. Lancet 2000; 355:808-809.
25. Suzuki H, Torigoe K, Numata O, et al. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000; 11:1277-1280.
26. Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27:1061-1070.
27. Martini B, Nava A, Thiene G, et al. Ventricular fibrillation without apparent heart disease: description of six cases. Am Heart J 1989; 118:1203-1209.
28. Frustaci A, Priori SG, Pieroni M, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation 2005; 112:3680-3687.
29. Coronel R, Casini S, Koopmann TT, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005; 112:2769-2777.
30. Papavassiliu T, Wolpert C, Fluchter S, et al. Magnetic resonance imaging findings in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004; 15:1133-1138.
31. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40:1437-1444.
32. Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004; 25:879-884.
33. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293-296.
34. Dumaine R, Towbin JA, Brugada P, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999; 85:803-809.
35. Veldkamp MW, Viswanathan PC, Bezzina C, et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. Circ Res 2000; 86:E91-E97.
36. Wang DW, Makita N, Kitabatake A, et al. Enhanced Na(+) channel intermediate inactivation in Brugada syndrome. Circ Res 2000; 87:E37-E43.
37. Rivolta I, Abriel H, Tateyama M, et al. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem 2001; 276:30623-30630.
38. Clancy CE, Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 2002; 105:1208-1213.
39. Mohler PJ, Rivolta I, Napolitano C, et al. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. Proc Natl Acad Sci U S A 2004; 101:17533-17538.
40. Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2006; 113:338-344.
41. Ito H, Yano K, Chen R, et al. The prevalence and prognosis of a Brugada-type electrocardiogram in a population of middle-aged Japanese-American men with follow-up of three decades. Am J Med Sci 2006; 331:25-29.
42. Poelzing S, Forleo C, Samodell M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation 2006; 114:368-376.
43. Baroudi G, Acharfi S, Larouche C, et al. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. Circ Res 2002; 90:E11-E16.
44. Rossenbacker T, Schollen E, Kuiperi C, et al. Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy. J Med Genet 2005; 42:e29.
45. Hong K, Guerchicoff A, Pollevick GD, et al. Cryptic 50 splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol 2005; 38:555-560.
46. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12:268-272.
47. Tukkie R, Sogaard P, Vleugels J, et al. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 2004; 109:1272-1277.
48. Shimizu W, Aiba T, Kurita T, et al. Paradoxic abbreviation of repolarization in epicardium of the right ventricular outflow tract during augmentation of Brugada-type ST segment elevation. J Cardiovasc Electrophysiol 2001; 12: 1418-1421.
49. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442-449.
50. London B, Sanyal S, Michalec M, et al. A mutation in the glycerol-3-phosphate dehydrogenase 1-like gene (GPD1L) causes Brugada syndrome. Heart Rhythm 2006; 3:S32. [abstract].
51. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the ACC/AHA Task Force and the ESC Committee for Practice Guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385-e484.
52. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105:1342-1347.
53. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007; 28:334-344.
54. Ikeda T, Takami M, Sugi K, et al. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann Noninvasive Electrocardiol 2005; 10:396-403.
55. Tatsumi H, Takagi M, Nakagawa E, et al. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc Electrophysiol 2006; 17:705-711.
56. Ajiro Y, Hagiwara N, Kasanuki H. Assessment of markers for identifying patients at risk for life-threatening arrhythmic events in Brugada syndrome. J Cardiovasc Electrophysiol 2005; 16:45-51.
57. Napolitano C, Grillo M, Suliman I, et al. Prevalence of late potentials in large population of patients with Brugada syndrome: implications for risk stratification [abstract]. Circulation 2003; 108.
58. Brugada P, Brugada R, Mont L, et al. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003; 14:455-457.
59. Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005; 111:257-263.
60. Brugada P, Brugada R, Brugada J, et al. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005; 112:279-292.
61. Priori SG, Napolitano C. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation 2005; 112:279-292.
62. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation 2006; 114:2317-2324. This multicenter French-Japanese study reports data on a large cohort of BrS patients implanted with an ICD. It is the first study on this scale and led to important insights into the use of the device in BrS patients.
63. Gehi A, Duong T, Metz L, et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol 2006; 17:577-583. This metaanalysis ties together the most important prognostic studies on BrS.
64. Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997; 95:2277-2285.
65. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus beta-blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. Circulation 2003; 107:2221-2226.
66. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110:1731-1737.
67. Valdivia CR, Ackerman MJ, Tester DJ, et al. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc Res 2002; 55:279-289.
68. Valdivia CR, Tester DJ, Rok BA, et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res 2004; 62:53-62.
69. Heidbuchel H, Corrado D, Biffi A, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: Ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil 2006; 13:676-686.
70. Tanaka H, Kinoshita O, Uchikawa S, et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2001; 24:1293-1294.
71. Maury P, Couderc P, Delay M, et al. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace 2004; 6: 130-133.
72. Watanabe A, Fukushima Kusano K, Morita H, et al. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome. Eur Heart J 2006; 27:1579-1583.
73. Marquez MF, Rivera J, Hermosillo AG, et al. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol 2005; 28:870-873.
74. Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003; 108:925-928.
75. Silva RM, Mont L, Nava S, et al. Radiofrequency catheter ablation for arrhythmic storm in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2004; 27:971-975.